Allogene Therapeutics Inc. Common Stock (ALLO)

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also d…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

150

Website

allogene.com/

Fundamentals

1-day range

$2$2.09

Market cap

$635.08M

P/E (trailing)

—

P/E (forward)

-2.88

EPS (trailing)

$-0.87

Dividend yield

—

Beta

0.55

Avg. volume

7.72M

Forecasts

9 analyst ratings

Allogene Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALLO

  Allogene Therapeutics Inc. Common Stock

  $2.01

  ▼ 3.83%
  Market cap $635.08MP/E —
  $1.04$4.46
• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $13.17

  ▼ 4.84%
  Market cap $665.83MP/E —
  $8.75$17.82
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $555.49MP/E —
  $5.37$17.58
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $527.47MP/E —
  $5.97$16.93
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $524.39MP/E —
  $1.88$7.44
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $507.54MP/E —
  $2.67$6.94

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?
  SeekingAlpha · 8/28/2026
• Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target
  benzinga · 8/17/2026
• Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target
  Benzinga · 8/17/2026
• Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Allogene Therapeutics Files Prospectus For $500M Offering
  Benzinga · 8/12/2026
• Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
  Benzinga · 8/12/2026

• Earl Martin Douglas · August 21, 2026 · Sale

  29.7K @ $2.12
• Zachary Roberts · July 1, 2026 · Grant

  476.2K
• Zachary Roberts · July 1, 2026 · Grant

  134.5K
• Barrett Elizabeth A. · June 18, 2026 · Grant

  95.4K
• Deborah M. Messemer · June 18, 2026 · Grant

  95.4K
• Stephen Mayo · June 18, 2026 · Grant

  144.4K
• WITTE OWEN N. · June 18, 2026 · Grant

  95.4K
• Humer Franz B · June 18, 2026 · Grant

  95.4K
• Joshua A. Kazam · June 18, 2026 · Grant

  95.4K
• Joshua A. Kazam · June 18, 2026 · Option Exercise

  47.7K
• Vicki L. Sato · June 18, 2026 · Grant

  95.4K
• Annie Yoshiyama · April 21, 2026 · Sale

  9.6K @ $2.31
• Benjamin Machinas Beneski · March 31, 2026 · Sale

  2.9K @ $2.5
• Benjamin Machinas Beneski · March 16, 2026 · Sale

  4.8K @ $2.47
• David D. Chang · March 16, 2026 · Sale

  47.8K @ $2.47

Institutional Ownership

March 31, 2026

Total shares held

180.17M

Total value held

$419.65M

Institutional holders

203